Read success stories about NRC research, and how our work contributes to the success of our clients and partners.





- Ottawa, Ontario

Research Centre: Human Health Therapeutics
•demonstrated that ZV can cross the blood-brain barrier
•showed that ZV infects glioblastoma cells to varying degrees, suggesting that genetically modified ZV could be developed to target therapeutics to glioblastoma cells
•developed a robust mouse model of ZV infection to test potential Zika vaccines
The NRC further leveraged its business relationship with Variation Biotechnologies Inc. (VBI) to bring the company's proprietary vaccine platform into this global effort to fight the emerging Zika epidemic. To this end, VBI and the NRC submitted a joint ZV grant proposal to the National Institute of Health. This strategic collaboration between VBI and the NRC has already led to the development of a plaque reduction neutralization assay at the NRC, and a collaborative research agreement to evaluate VBI's candidate enveloped virus-like particle (eVLP) vaccines is underway.